Pfiz­er launch­ing first US mAb biosim­i­lar with Rem­i­cade knock­off, but you can for­get about any fire sale

Pfiz­er $PFE plans to launch the first mAb copy­cat and the sec­ond biosim­i­lar ever in the US in the next few weeks. But the price will look al­most as close to the orig­i­nal as the drug it­self, as Pfiz­er will on­ly cut 15% off the whole­sale price for this pi­o­neer­ing biosim­i­lar.

Dubbed In­flec­tra (in­flix­imab-dyyb), the ther­a­py is a xe­rox of Rem­i­cade, a main­stay bi­o­log­ic that has bol­stered J&J $JNJ for years. De­vel­oped by South Ko­rea’s Cell­tri­on, Pfiz­er bagged the US com­mer­cial­iza­tion rights with its ac­qui­si­tion of Hos­pi­ra, which part­nered with Cell­tri­on. And Cell­tri­on has been steadi­ly eat­ing in­to Mer­ck’s fran­chise rev­enue from Rem­i­cade af­ter be­gin­ning sales in Eu­rope last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER